अApnaFunda
Menu

ALKEM LABORATORIES LIMITED (ALKEM)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.69 / 100
Profitability 67Growth 60Balance sheet 81
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.62 / 100
Price 57Earnings 39FII/DII 89

Passes these screensCash RichDebt-light & profitable

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹5,398.5 latest close · −2.9% over the last 90 sessions

₹5,000₹5,500Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹5,000₹5,500Jul 3Sep 4Nov 9

₹5,398.5 month-end · −5.0% over 12 months

₹5,200₹5,400₹5,600₹5,800Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹5,200₹5,400₹5,600₹5,800Nov '25May '26Nov '26

₹5,398.5 month-end · +14.3% over 3 years

₹4,500₹5,000₹5,500₹6,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹4,500₹5,000₹5,500₹6,000Nov '23May '25Nov '26

₹5,398.5 month-end · +186.7% since Jan '19

₹2,000₹4,000₹6,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹2,000₹4,000₹6,000Jan '19Dec '22Nov '26

52-week range ₹4811.00 to ₹5933.50 · 1-year volatility 22.1%

Was the rally earned?

-5%share price, 1 yearEarnings-driven

Mostly earnings.

  • Per-share earnings took off 6 points, while the multiple moved less (P/E 29.8x to 29.9x).
  • The share count fell 2%.
Net profit growth: −8 pts. Points of the price return explained by net profit growing (or shrinking).−8 ptsNet profit growthP/E change: +1 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+1 ptsP/E changeShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2 ptsShare count changeShare price: −5%−5%Share priceNet profit growth: −8 pts. Points of the price return explained by net profit growing (or shrinking).−8ProfitP/E change: +1 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+1P/EShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2SharesShare price: −5%−5%Share price
Net profit growth-8 ptsNet profit fell about 8%, which lowers the price.
P/E change+1 ptsThe P/E rose from 29.8x to 29.9x, which lifts the price.
Share count change+2 ptsShare count fell 2%, which lifts the price.
+14%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 84 points, but investors now pay less per rupee of profit (P/E 57.4x to 29.9x), which took 70 points back.
  • The share count fell 2%.
Net profit growth: +82 pts. Points of the price return explained by net profit growing (or shrinking).+82 ptsNet profit growthP/E change: −70 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−70 ptsP/E changeShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3 ptsShare count changeShare price: +14%+14%Share priceNet profit growth: +82 pts. Points of the price return explained by net profit growing (or shrinking).+82ProfitP/E change: −70 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−70P/EShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3SharesShare price: +14%+14%Share price
Net profit growth+82 ptsNet profit rose about 114%, which lifts the price.
P/E change-70 ptsThe P/E fell from 57.4x to 29.9x, which lowers the price.
Share count change+3 ptsShare count fell 2%, which lifts the price.
+50%share price, 5 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 38 points to the rise, while the multiple moved less (P/E 27.1x to 29.9x).
  • The share count fell 2%.
Net profit growth: +36 pts. Points of the price return explained by net profit growing (or shrinking).+36 ptsNet profit growthP/E change: +12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+12 ptsP/E changeShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3 ptsShare count changeShare price: +50%+50%Share priceNet profit growth: +36 pts. Points of the price return explained by net profit growing (or shrinking).+36ProfitP/E change: +12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+12P/EShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3SharesShare price: +50%+50%Share price
Net profit growth+36 ptsNet profit rose about 33%, which lifts the price.
P/E change+12 ptsThe P/E rose from 27.1x to 29.9x, which lifts the price.
Share count change+3 ptsShare count fell 2%, which lifts the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-28.3%not yet recovered
1-year volatility22.1%annualised
Beta vs sector index0.853-year daily, correlation 0.52
Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%2020202120222023202420252026−27.7% 0%−10%−20%2020202220242026−27.7%
Largest drawdowns

-28.3% (2024-09 peak to 2025-02 low, not yet recovered)

-27.5% (2021-09 peak to 2022-05 low, recovered 2023-07)

-18.5% (2020-04 peak to 2020-05 low, recovered 2020-08)

Most recent volume spikes

2026-08-14: 5.8x the 50-day median, price -1.5% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

29.9xP/E todayWithin its usual range
Against its own history60th percentile
CheapestMedian 28.9xDearest

Usual range 23.9x to 44.1x since 2019-01.

Against Health Technology29.9x vs 37.0x
This company
29.9x
Sector median
37.0x

19% below the Health Technology median.

16.7x32.2x47.7x63.2xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x32.2x47.7x63.2xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE74thflat vs a year ago
  • Op. margin59th▼ 7 pts vs a year ago
  • Revenue growth55th▲ 19 pts vs a year ago
  • EPS growth32nd▼ 22 pts vs a year ago
  • Debt/equity ↓61stflat vs a year ago
  • Cash cycle ↓51stflat vs a year ago
  • P/E ↓61st▲ 7 pts vs a year ago
  • 12M momentum33rd▼ 35 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~21%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 36.4x, a holder earning 12%/yr needs earnings to grow about 20.9%/yr for 10 years, then trade at 15x.

Delivered15.6%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+5.3 ptsimplied minus delivered
Rank417thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%13%25% Jan 2019Nov 2026 0%13%25% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x22.3%23.4%24.5%
15x19.8%20.9%22.0%
20x16.6%17.7%18.7%

Drag a slider to test other assumptions

Implied: 20.9%/yr

Looking back

  • Jan 2020Price implied 23%/yr; EPS has since grown 17%/yr (7.0 yrs)
  • Jan 2021Price implied 23%/yr; EPS has since grown 13%/yr (6.0 yrs)
  • Jan 2022Price implied 23%/yr; EPS has since grown 8%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹5398.50
P/E
29.9x
ROCE
21.0%
Market Cap
₹64541 cr
Revenue (TTM)
₹15081 cr
P/S
4.3x
P/B
4.7x
ROE
15.6%
Operating Margin
20.0%
Debt / Equity
0.1x
Promoter Holding
49.7%
12M Momentum
-5.0%

52-week range

₹4811.00₹5933.50
52% of the way from its 52-week low to its high

Price risk

1Y volatility
22.1%
Beta vs sector
1-year daily
0.83

Balance sheet & cash

Interest cover
operating profit ÷ interest
17.1x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.91x
Share count, 1Y
unchanged

Are profits backed by cash?

5 of 7checks within range2 near a threshold
Other income reliance14%Within range

Other income as a share of pre-tax profit (trailing twelve months): 14.3%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate15%Near threshold

Median quarterly effective tax rate over about 2.5 years: 14.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.91xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.91x (cash from operations ₹5,824 cr, net profit ₹6,377 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+7 daysWithin range

Debtor days are above the median of the previous three fiscal years by 7 days (74 vs 67). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress7% of fixed assetsWithin range

Capital work-in-progress is 7% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+32 days / 2 yrsNear threshold

Days payable changed by +32 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, promoters trimmed 7.0 pts; DIIs added 5.0 pts; FIIs added 4.4 pts.
  • The number of shareholders fell from 69,442 to 62,822 (-10%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters56.7%49.7%-7.0 pts
FIIs6.0%10.4%+4.4 pts
DIIs17.6%22.6%+5.0 pts
Public and others19.6%17.3%-2.3 pts

Number of shareholders

62,822shareholders-10% since Sep '23
63k70k77k84k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 69,442
Dec '23: 65,184
Mar '24: 65,830
Jun '24: 69,627
Sep '24: 74,744
Dec '24: 84,038
Mar '25: 84,326
Jun '25: 79,740
Sep '25: 67,196
Dec '25: 64,536
Mar '26: 62,835
Jun '26: 62,822
 63k70k77k84k Sep '23Sep '24Sep '25Jun '26
Sep '23: 69,442
Dec '23: 65,184
Mar '24: 65,830
Jun '24: 69,627
Sep '24: 74,744
Dec '24: 84,038
Mar '25: 84,326
Jun '25: 79,740
Sep '25: 67,196
Dec '25: 64,536
Mar '26: 62,835
Jun '26: 62,822

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−9.7%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like ALKEM LABORATORIES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −21% to +10% vs the market, against −7% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −3.2%, 80% range −8.7% to −1.0%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−40%−20%0%+20%+40%+60%
LTTS · Feb 2025: −34.4% vs market
CONCOR · Feb 2024: −33.5% vs market
MRF · Nov 2020: −32.0% vs market
DEEPAKNTR · Sep 2024: −31.6% vs market
COROMANDEL · Jan 2021: −31.3% vs market
EXIDEIND · Apr 2020: −29.2% vs market
ACC · Jun 2022: −28.8% vs market
SYNGENE · Oct 2024: −26.3% vs market
HCLTECH · Feb 2025: −25.3% vs market
SUNDRMFAST · Sep 2023: −25.0% vs market
GALAXYSURF · Jun 2022: −24.4% vs market
GODREJCP · Oct 2025: −22.7% vs market
PIIND · Apr 2025: −21.3% vs market
AIAENG · Aug 2023: −21.1% vs market
GODREJAGRO · Jan 2020: −19.7% vs market
DRREDDY · Jul 2023: −18.9% vs market
BERGEPAINT · Apr 2025: −18.5% vs market
MPHASIS · Aug 2025: −17.0% vs market
BALKRISIND · Mar 2025: −16.2% vs market
KAJARIACER · Dec 2021: −13.3% vs market
HAVELLS · Aug 2024: −12.9% vs market
HEROMOTOCO · Jan 2024: −11.2% vs market
DABUR · Feb 2025: −11.0% vs market
VGUARD · Mar 2023: −10.8% vs market
ATUL · Jun 2021: −10.6% vs market
AMBUJACEM · Aug 2021: −8.9% vs market
CIPLA · Dec 2022: −8.8% vs market
TECHM · Feb 2020: −8.7% vs market
SHREECEM · Jan 2025: −8.5% vs market
BOSCHLTD · Jun 2024: −6.1% vs market
KPRMILL · Mar 2025: −6.0% vs market
HAPPYFORGE · Jan 2025: −5.5% vs market
JBCHEPHARM · Aug 2024: −3.0% vs market
SUNPHARMA · Jun 2023: −1.3% vs market
SUPREMEIND · Sep 2020: +1.9% vs market
LUPIN · Aug 2025: +7.2% vs market
VOLTAS · Sep 2020: +9.4% vs market
ENDURANCE · May 2025: +9.5% vs market
RATNAMANI · Mar 2021: +10.4% vs market
POLYCAB · Jun 2021: +11.4% vs market
ULTRACEMCO · Sep 2024: +12.2% vs market
LALPATHLAB · May 2025: +12.9% vs market
ZYDUSLIFE · Jan 2024: +18.0% vs market
ERIS · Nov 2023: +19.2% vs market
TORNTPHARM · Jun 2024: +19.6% vs market
CUMMINSIND · Sep 2022: +22.2% vs market
BAJAJ-AUTO · Oct 2025: +23.0% vs market
UNITDSPR · Apr 2024: +30.7% vs market
SFL · Dec 2020: +37.5% vs market
WIPRO · May 2020: +45.4% vs market
Similar setups −9.7%All companies −6.5%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median
−9.7%
All companies' median
−6.5%
Beat the market
32% vs 43%

50 past situations · 50 companies · 35 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
DABUR
Consumer Non-Durables		 Feb 2025 49x22% −8%−26% −11%
TECHM
Technology Services		 Feb 2020 16x25% −11%−12% −9%
BERGEPAINT
Process Industries		 Apr 2025 56x28% +7%−13% −19%
MRF
Consumer Durables		 Nov 2020 23x13% +23%−3% −32%
SUNDRMFAST
Producer Manufacturing		 Sep 2023 54x19% +39%−3% −25%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CIPLA
Health Technology		 Dec 2022 35x17% +14%−8% −9%
WIPRO
Technology Services		 May 2020 14x19% −26%−29% +45%
BAJAJ-AUTO
Consumer Durables		 Oct 2025 33x28% −7%−9% +23%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ALKEM LABORATORIES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

KAJARIA CERAMICSKAJARIACER
Producer Manufacturing
73%similar
operating marginpromoter holding
EICHER MOTORSEICHERMOT
Consumer Durables
66%similar
promoter holdingrevenue
UNITED SPIRITSUNITDSPR
Consumer Non-Durables
66%similar
revenuemarket cap
EIHEIHOTEL
Consumer Services
65%similar
ROCEEPS growth
SUNDRAM FASTENERSSUNDRMFAST
Producer Manufacturing
65%similar
debt/equitypromoter holding
AUROBINDO PHARMAAUROPHARMA
Health Technology
72%similar
P/Eoperating margin
IPCA LABORATORIESIPCALAB
Health Technology
72%similar
market caprevenue
SUN PHARMACEUTICAL INDUSTRIESSUNPHARMA
Health Technology
70%similar
ROCEvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since May '23

  1. SepResultsYear-on-year EPS growth turned negative.
  2. SepPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  3. AugPriceVolume reached 5.8x its 50-day median on 2026-08-14; price -1.5% that day.
  4. JunPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  5. MayPriceVolume reached 13.4x its 50-day median on 2026-05-29; price +0.9% that day.
  6. FebPriceVolume reached 7.5x its 50-day median on 2026-02-13; price -8.0% that day.
  7. SepPromoterPromoter holding fell 2.1 pts to 53.0%.
  8. SepPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
Show 22 earlier events
  1. AugPriceVolume reached 9.6x its 50-day median on 2025-08-12; price +6.3% that day.
  2. JunPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  3. MayPriceVolume reached 8.6x its 50-day median on 2025-05-30; price -3.7% that day.
  4. MarResultsRevenue (TTM) reached a new high of ₹12,757 cr.
  5. FebPriceFell 28% from the Sep 2024 peak to the Feb 2025 low.
  6. FebPriceVolume reached 7.8x its 50-day median on 2025-02-10; price -6.8% that day.
  7. DecInstitutionsFII + DII holding rose 3.5 pts over 2 quarters to 28.2%.
  8. NovPriceVolume reached 33.1x its 50-day median on 2024-11-25; price -1.9% that day.
  9. SepPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  10. AugPriceVolume reached 7.7x its 50-day median on 2024-08-09; price +1.9% that day.
  11. JunResultsYear-on-year EPS growth turned positive.
  12. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  13. JunDividendDividend payout cut from 61% to 27% of profit.
  14. MayPriceVolume reached 9.0x its 50-day median on 2024-05-30; price -6.0% that day.
  15. FebPriceVolume reached 12.8x its 50-day median on 2024-02-26; price -6.6% that day.
  16. DecPriceVolume reached 10.3x its 50-day median on 2023-12-15; price +1.3% that day.
  17. AugPriceVolume reached 6.5x its 50-day median on 2023-08-11; price -7.7% that day.
  18. JulPriceRegained the 2021-09 peak, 14 months after the low.
  19. JunResultsYear-on-year EPS growth turned negative.
  20. JunValuationP/E crossed above the 90th percentile of its own history to date (42.7x).
  21. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  22. MayPriceVolume reached 5.8x its 50-day median on 2023-05-09; price +3.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1129.9x₹15081 cr15.6%21.0%0.1x
2026-1028.3x₹15081 cr15.9%21.0%0.1x
2026-0928.6x₹15081 cr15.9%21.0%0.1x
2026-0827.7x₹14712 cr17.0%21.0%0.1x
2026-0729.9x₹14712 cr17.0%21.0%0.1x
2026-0628.9x₹14712 cr17.0%21.0%0.1x
2026-0527.7x₹14253 cr20.2%20.0%0.1x
2026-0427.2x₹14253 cr20.2%20.0%0.1x
2026-0326.7x₹14253 cr20.2%20.0%0.1x
2026-0228.6x₹13890 cr20.1%20.0%0.1x
2026-0128.8x₹13890 cr20.1%20.0%0.1x
2025-1227.9x₹13890 cr20.1%20.0%0.1x
2025-1129.8x₹13304 cr19.5%20.0%0.1x
2025-1028.8x₹13304 cr19.5%20.0%0.1x
2025-0928.4x₹13304 cr19.5%20.0%0.1x
2025-0829.3x₹12965 cr18.5%20.0%0.1x
2025-0727.8x₹12965 cr18.5%20.0%0.1x
2025-0627.3x₹12965 cr18.5%20.0%0.1x
2025-0528.3x₹12757 cr21.3%20.0%0.1x
2025-0428.4x₹12757 cr21.3%20.0%0.1x
2025-0327.1x₹12757 cr21.3%20.0%0.1x
2025-0226.2x₹12707 cr20.9%20.0%0.1x
2025-0128.5x₹12707 cr20.9%20.0%0.1x
2024-1231.7x₹12707 cr20.9%20.0%0.1x
2024-1132.8x₹12732 cr20.1%20.0%0.1x
2024-1033.6x₹12732 cr20.1%20.0%0.1x
2024-0935.2x₹12732 cr20.1%20.0%0.1x
2024-0841.1x₹12668 cr17.6%20.0%0.1x
2024-0735.4x₹12668 cr17.6%20.0%0.1x
2024-0633.2x₹12668 cr17.6%20.0%0.1x
2024-0558.4x₹11599 cr11.1%14.0%0.2x
2024-0458.7x₹11599 cr11.1%14.0%0.2x
2024-0360.0x₹11599 cr11.1%14.0%0.2x
2024-0262.3x₹11599 cr11.1%14.0%0.2x
2024-0160.7x₹11599 cr11.1%14.0%0.2x
2023-1263.2x₹11599 cr11.1%14.0%0.2x
2023-1157.4x₹11599 cr11.1%14.0%0.2x
2023-1045.2x₹11599 cr11.1%14.0%0.2x
2023-0943.8x₹11599 cr11.1%14.0%0.2x
2023-0844.3x₹11599 cr11.1%14.0%0.2x
2023-0748.3x₹11599 cr11.1%14.0%0.2x
2023-0642.7x₹11599 cr11.1%14.0%0.2x
2023-0524.4x₹10634 cr19.4%18.0%0.3x
2023-0425.5x₹10634 cr19.4%18.0%0.3x
2023-0324.7x₹10634 cr19.4%18.0%0.3x
2023-0223.1x₹10634 cr19.4%18.0%0.3x
2023-0121.9x₹10634 cr19.4%18.0%0.3x
2022-1221.8x₹10634 cr19.4%18.0%0.3x
2022-1122.7x₹10634 cr19.4%18.0%0.3x
2022-1022.9x₹10634 cr19.4%18.0%0.3x
2022-0923.8x₹10634 cr19.4%18.0%0.3x
2022-0821.6x₹10634 cr19.4%18.0%0.3x
2022-0723.4x₹10634 cr19.4%18.0%0.3x
2022-0621.8x₹10634 cr19.4%18.0%0.3x
2022-0523.8x₹8865 cr21.9%22.0%0.2x
2022-0424.5x₹8865 cr21.9%22.0%0.2x
2022-0327.3x₹8865 cr21.9%22.0%0.2x
2022-0224.7x₹8865 cr21.9%22.0%0.2x
2022-0126.7x₹8865 cr21.9%22.0%0.2x
2021-1227.3x₹8865 cr21.9%22.0%0.2x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback